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Abstract 
Introduction 
Alcoholic liver disease (ALD) and type 2 diabetes mellitus (T2DM) are two important chronic 
diseases in Australia, both of which are emerging epidemics. As a result, patients presenting with both 
conditions may become increasingly more common. However, not much is known about how each 
affects the other in terms of clinical outcomes. 
 
Methods 
Evidence from studies exploring the relationship between T2DM and ALD, including those pertaining 
to liver function tests (LFT) and hepatocellular carcinoma (HCC), was reviewed and summarised. 
 
Results 
There are studies which show that high alcohol intake and chronic liver disease (CLD) are risk factors 
of developing T2DM. Conversely, having impaired glucose tolerance has been shown to promote 
progression of CLD. There is also some evidence of increased risk of HCC in patients with T2DM and 
who consume alcohol in the context of other liver disease. However, no studies that looked into how 
T2DM directly affects LFT results in ALD were found. 
 
Discussion 
There seems to be a bidirectional relationship between T2DM and ALD, although it is not explicitly 
cause-and-effect in nature. Hence, there is a need for a comprehensive management plan that utilises a 
multidisciplinary approach to minimise the risk of complications for patients with either or both 
diseases. Currently, this is not available and both diseases are treated as separate entities. Therefore, 
further research must be done to elucidate the relationship between the two, so that effective strategies 
to manage co-existing T2DM and ALD can be developed. 
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Introduction 
 
Alcoholic liver disease (ALD) is an important 
chronic disease in Australia, which is 
characterised by long-standing hepatocellular 
damage as a result of excess alcohol 
consumption. ALD represents a spectrum of 
alcohol-related liver diseases of increasing 
severity - alcoholic steatosis (alcoholic fatty 
liver disease), alcoholic steatohepatitis and 
alcoholic liver cirrhosis as well as acute 
alcoholic hepatitis1. The prevalence of ALD 
itself is difficult to determine as most cases are 
diagnosed late in the course of the disease. In 
2012, it was estimated there were at least 6,203 
alcohol-related liver disease cases in Australia. 
There is an increasing trend of ALD and an 
addition of more than 1,000 new cases are 
expected by 20302. 
 
Two key mechanisms of damage due to chronic 
alcohol consumption have been proposed. 
Firstly, ethanol molecule causes oxidative stress 
and hepatocyte inflammation, leading to liver 
damage3. This is mediated by the generation of 
reactive oxygen species as a by-product of 
ethanol metabolism, which causes 
mitochondrial glutathione depletion, and thus in 
sensitization of hepatocytes to injury. 
 
Secondly, alcohol consumption, by promoting 
enteric bacterial overgrowth and increasing gut 
mucosal permeability, facilitates translocation 
of endotoxin to the bloodstream, and 
subsequently to the liver. These result in 
endotoxin-mediated complement cascade and 
Kupffer cell activation with the generation of 
TNF-α, a pro-inflammatory cytokine, which 
induces hepatocyte injury4. While Kupffer cells 
are also known for their role in initiating 
hepatoprotective and anti-inflammatory 
responses through the same pathway, these 
mechanisms seem to be inhibited in chronic 
alcohol consumption4. This imbalance between 
anti-oxidative mechanisms and oxidative stress 
imposed on hepatocytes in chronic alcoholism, 
in association with the release of inflammatory 
mediators due to endotoxemia are the principal 
mediators for the progression of ALD. 
 
A few established risk factors for ALD have 
been documented in the literature. Non-
modifiable risk factors include sex, with women 
developing more severe disease than men even 
with lower absolute amounts of alcohol 
consumption, and genetic variations such as the 
PNPLA3 variant3, 5. Modifiable risk factors 
include smoking6 and most importantly, 
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aggressive drinking behaviours such as binge 
drinking and chronic high dose consumption3. 
 
On the other hand, Type 2 Diabetes Mellitus 
(T2DM) is considered to be an epidemic in 
Australia, with an estimated 848,000 
Australians currently suffering from the 
condition. Furthermore, from 1989 to 2012, the 
number of diabetes diagnoses (T1DM and 
T2DM) has almost tripled7. 
The Australian Bureau of Statistics have 
reported that up to 10.7% of Australians with 
T2DM display high-risk alcohol drinking 
behaviour8. Increasing prevalence of T2DM and 
ALD may eventually translate to more patients 
being diagnosed with both conditions.  Their 
co-existence in one patient may prove to be 
catastrophic, as they independently increase the 
risk of poor liver outcomes 3, 9. 
 
Only a single study has been documented in the 
literature which examines the relationship 
between ALD and T2DM. Kotronen et al.10 
found that the prevalence of T2DM in alcoholic 
fatty liver disease patients approximates that in 
non-alcoholic fatty liver disease (NAFLD) at 
~25%, which is much higher than that in the 
general population. The objective of this paper 
is to review the relationship between T2DM and 
ALD by examining liver outcomes in terms of 
liver function tests (LFTs) and a subsequent 
complication of hepatocellular carcinoma 
(HCC). Improved management options will be 
discussed in relation to an anticipated worse 
prognosis in patients with dual diagnosis. 
Methodology 
A comprehensive literature search for relevant 
articles from inception to December 2013 was 
performed on MEDLINE, Scopus and 
Discovery (The University of Melbourne) for 
original research and review articles using the 
key words: “Liver Diseases, Alcoholic” and 
“Diabetes Mellitus, Type 2”. Quantitative 
studies that explored the relationship between 
ALD and T2DM were included. Exclusion 
criteria include studies qualitative studies, 
duplicate articles, conference abstracts and non-
English articles. In addition, a manual search 
was performed via Google Scholar and for the 
reference lists of relevant studies and reviews. 
Initial search yielded 1243 articles for abstract 
screening. Of these, 12 studies were included in 
our review following assessment of abstracts 
and full-text articles. Studies selected for 
analysis were further divided by topic: data on 
liver function tests (LFTs), hepatocellular 
carcinoma (HCC) and articles presenting known 
data on comorbidity between ALD and T2DM. 
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Researcher triangulation was achieved through 
having four investigators appraise and 
synthesise the evidence from each article. 
 
Results 
 
1.         Liver Function Tests (LFTs) of ALD 
and T2DM patients 
 
A. Gamma-GlutamylTransferase (GGT) 
 
Whilst GGT levels are only moderately 
correlated with excessive alcohol 
consumption11, GGT was found to be markedly 
elevated in ALD as an established diagnosis12. 
Compared to non-alcoholic steatohepatitis 
(NASH), the average GGT level in ALD is 
significantly higher (NASH: 68.7 IU/L vs ALD: 
496.9 IU/L)12. Furthermore, it has been found 
that in people with baseline obesity, GGT 
increases with just mild alcohol consumption11. 
 
B. The Transaminases - Aspartate 
Aminotransferase (AST) and Alanine 
Aminotransferase (ALT) 
 
AST is more specific to the liver than ALT by 
histopathological evidence. Across the spectrum 
of ALD, alcoholic steatosis only causes 
minimal elevation, while in alcoholic 
steatohepatitis, the value goes up to 500 U/L11. 
This is also supported by another study in 
which aminotransaminases were found to be 
only slightly elevated in patients with alcoholic 
steatosis (mean AST 54.1 U/L, ALT 72.8 U/L), 
but were grossly increased in those with 
alcoholic steatohepatitis (mean AST 668.2 U/L, 
ALT 399.8 U/L). On the other hand, NASH 
exhibits a similar pattern of mild elevation of 
aminotransaminases as alcoholic steatosis 
(mean AST 67.2, ALT 117.6). However, in 
advanced disease with liver cirrhosis, these 
markers are not reliable in indicating liver 
damage11. 
 
In a study where patients with T2DM were 
screened, up to 28% of patients demonstrated 
generalised elevation of LFT results. Of these, 
65% were subsequently diagnosed with non-
alcoholic steatosis and 87% demonstrated 
steatosis by ultrasound criteria13.  
 
Our search did not retrieve studies that directly 
looked at how T2DM influences LFT results in 
ALD. 
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2.         Hepatocellular Carcinoma (HCC) 
 
Daily ethanol consumption of ≥80mL and ≥160 
mL results in an exponential increase in the risk 
of a person developing HCC 5-fold and 25-fold, 
respectively14. Whilst the impact of T2DM 
alone on the risk of HCC is not well-
documented, there is some evidence to support 
the notion of excess risk of HCC in patients 
with liver disease and co-morbid T2DM. A 
study has reported a 10-fold increase in the risk 
of progression to HCC when T2DM is 
combined with chronic viral hepatitis and 
hazardous drinking9. Balbi et al.15 further 
documents an increased risk of HCC in the 
presence of both T2DM and alcohol 
consumption (OR = 49.0 with (95% CI 
21.5−111.8; P < 0.0001)) compared to alcohol 
consumption alone (OR = 3.7 with (95% CI 
2.5−5.4; P < 0.0001). Finally, Hassan et al.14 
reports a synergy index between alcohol 
consumption and diabetes in increasing HCC 
risk of 2.9 (1.3-4.6). 
 
3.         The Relationship between T2DM and 
ALD 
 
It has been noted that there are some 
associations between ALD and T2DM9. 
 
Garcia-Compean et al.16 reported a 2-fold 
increase of T2DM risk in patients who consume 
≥270 grams of alcohol/week compared with 
those who consume ≤120 grams/week. Not 
surprisingly, patients with chronic liver disease 
(CLD) are prone to developing diabetes, as 
demonstrated by the following two studies. 
Holstein et al.17 found that 96% of their patients 
with cirrhosis have impaired glucose tolerance, 
of which 75% suffer from T2DM. In another 
CLD study, where 74.3% of participants had a 
diagnosis of ALD (of variable degree of disease 
severity), impaired glucose tolerance was also 
demonstrated. In patients with severe disease, 
69.8% were found to have impaired glucose 
tolerance, with 17.4% having diabetes18. 
 
Conversely, there exists some evidence in the 
literature that elucidate the impact of T2DM on 
liver function and development of ALD. One 
study showed that high blood glucose level is a 
risk factor for hepatic fibrosis (p<0.05). This 
applies both in ALD patients with (r = 0.11 +/- 
0.05; P = .027) or without (r = 0.115 +/- 0.045; 
P = .011) cirrhosis19. This is consistent with 
Garcia-Compean et al.16; Hickman & 
Macdonald9 and Picardi et al.20 who 
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emphasized that the presence of insulin 
resistance is a risk factor in the progression of 
any liver disease. 
 
Discussion 
The results of our literature review support the 
notion that there may indeed be a bidirectional 
relationship between ALD and T2DM, with 
both conditions having the potential to exert an 
influence in the development of the other. Of 
particular importance is the evidence regarding 
the prevalence of liver enzyme dysfunction in 
T2DM, the prevalence of prediabetes in ALD 
patients, and the synergistic relationship 
between T2DM and alcohol consumption in the 
context of other liver disease in the 
development of HCC. With evidence showing 
high prevalence of T2DM in ALD patients10, it 
is highly likely that patients will present with 
clinical features of both ALD and T2DM. Left 
untreated, numerous consequences can occur 
which will necessitate comprehensive 
management. Hence a holistic approach is 
recommended, incorporating facets of 
pharmacotherapy, social support, lifestyle 
modifications and most importantly, patient 
education.  
 
Currently, the management of ALD and T2DM 
as individual conditions is multi-faceted and 
dependent on disease severity. For ALD, 
alcohol abstinence is the key to preventing 
cirrhosis progression. Principal issues that must 
be addressed include both physiological and 
psychological dependence and the breakdown 
of daily routine of alcohol drinking21. This is 
achieved primarily through psychological 
support, psychotherapy and adjunct 
pharmacotherapy. Nutritional supplementation, 
notably B-vitamins, folate and protein, is also 
recommended22 as protein-calorie malnutrition 
is correlated with increased mortality, severity 
of liver disease and hepatic dysfunction. For 
patients with ALD that progresses to liver 
failure, the only cure that remains is liver 
transplantation. However, potential recipients 
are only eligible if they demonstrate 6 months 
of alcohol abstinence and have a low risk of 
continued alcohol abuse23. 
 
For T2DM management, the key objectives 
include symptom relief, prevention of disease 
progression and/or complications, as well as 
maintenance of quality of life24. Lifestyle 
modifications remain arguably the most 
effective treatment, with recent statistics 
revealing 80% of Australians with diabetes are 
overweight25. Referral to a dietician and 
consumption of a low-calorie, low-fat, low 
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glycaemic index and high-fibre diet should be 
encouraged. As an adjunct to dietary control, 
regular exercise has also been shown to 
improve blood glucose levels26, however care is 
necessitated to avoid resultant hypoglycaemia24. 
When these measures prove to be unsuccessful, 
medications such as metformin and 
sulfonylureas are considered. Insulin therapy is 
implemented if the treatment target for blood 
glucose levels is still not achieved24. In addition 
to glycaemic control, other cardiovascular 
disease (CVD) risk factors such as 
hypertension, dyslipidaemia, smoking and 
excess alcohol consumption need to be 
addressed simultaneously using conservative 
and/or medical treatments26. 
 
Additionally, due to the multiple complications 
that can arise from T2DM, close monitoring by 
a dedicated team of specialists is essential. 
These include regular follow-up for retinopathy 
and nephropathy by an ophthalmologist and a 
GP/nephrologist respectively. Neurologists are 
only necessary in cases of neuropathy. Allied 
health professionals are also recommended to 
partake in T2DM management. Close follow-up 
of foot health by a podiatrist is recommended 
for all T2DM patients, as peripheral vascular 
disease, in conjunction with peripheral 
neuropathy, is responsible for diabetic foot 
disease27. Finally, patient education is crucial 
for the success of diabetes management. Ideally 
carried out from the first diagnosis of T2DM, 
self-monitoring of blood glucose levels on an 
agreed frequency and appropriate use of a 
diabetes diary are simple but effective methods 
of diabetes monitoring24. Furthermore, as there 
is an increased risk of death in T2DM patients 
during hypoglycaemic events28, educating 
patients about what to do when medication side 
effects occur is of great importance. The 
delegation of care to a diabetes nurse specialist, 
who can assist with patient self-management, is 
an established practice in Australia29. 
 
In patients with co-existing ALD and T2DM, 
disease management becomes even more 
complicated. Preventing progression through 
alcohol abstinence is fundamental in such 
patients. However, in patients with ALD, 
alcohol abstinence continues to be a challenge 
due to many having a long history of 
dependence30. In addition, there are many 
socio-cultural factors that influence alcohol 
consumption, such as the use of alcohol in 
social events and the prevalence of alcohol 
advertisements in our society.  
 
In patients with progressive ALD, 
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pharmacotherapy, such as glucocorticoids, may 
be used to reduce inflammation. However, in 
patients with concurrent T2DM, they may be 
relatively contraindicated due to their potential 
to exacerbate blood glucose levels31. 
Furthermore, they can precipitate new-onset 
hyperglycemia in patients with subclinical 
diabetes32. Its alternative, pentoxifylline, has 
also been reported to potentially aggravate pre-
existing T2DM in patients33. Hence, there is no 
ideal pharmacotherapy for ALD with comorbid 
T2DM.  
 
Finally, in patients with liver failure, liver 
transplantation is complicated by the presence 
of CVD due to long-standing T2DM. Evidence 
has shown that the presence of pre-existing 
CVD and T2DM leads to poor prognosis post-
transplant34. This underlines the need of 
aggressive management of T2DM in the form 
of primary prevention through education and 
risk recognition, as well as achieving good 
control in patients with already established 
T2DM. Despite this, there is no standardisation 
of management of CVD available in the pre-
transplant period34.  
 
It is imperative that clinicians are aware of how 
treatment for one condition may impact on the 
other. A fine balance must be achieved to 
ensure minimal detriment to other 
comorbidities. However, currently there is not 
enough known about how those two diseases 
interact to achieve such fine balance. Therefore, 
more studies need to be done to better elucidate 
the effect of these diseases on each other. 
Further research on how to best manage these 
implications is also essential. Ultimately, a 
multidisciplinary team management is 
recommended, consisting of specialist clinicians 
well versed in treating T2DM and ALD, 
pharmacists, dieticians, along with nurse 
educators for patient education. In doing so, this 
maximises the chance of recovery whilst 
minimising risks of complications in patients 
who suffer from both conditions. 
 
Conclusion 
 
Currently, there is good evidence to suggest that 
there may be a bidirectional relationship 
between T2DM and ALD. Evidence in the 
literature has shown that ALD may influence 
the development of T2DM and vice versa. 
However, there is much less information 
regarding the effects of these two conditions on 
liver function when they occur together. This is 
a notable gap that is of significant importance, 
given the potential for worse liver outcomes 
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occurring in these patients in the face of 
epidemics of both conditions in Australia. As 
such, further research in the area needs to occur 
in order to develop well-defined strategies to 
prevent and manage the combined effects of 
T2DM and ALD should they occur 
concurrently. 
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